Cabio Biotech Wuhan Co Ltd (688089) — Cash Flow Quality Index

Latest as of September 2025: 2.62x

Cabio Biotech Wuhan Co Ltd (688089) has a Cash Flow Quality Index of 2.62x as of September 2025. Operating cash flow of CN¥56.10 Million exceeds net income of CN¥21.39 Million, indicating high earnings quality where cash backs reported profits. Also explore Cabio Biotech Wuhan Co Ltd balance sheet assets for the complete picture of this company's asset base.

Cash Flow Quality Index

2.62x
Operating CF / Net Income

Operating Cash Flow

CN¥56.10 Million
CNY

Net Income

CN¥21.39 Million
CNY

Data as of

Sep 2025
Most recent filing

Cabio Biotech Wuhan Co Ltd Cash Flow Quality Index (2013–2024)

Historical Cash Flow Quality Index for Cabio Biotech Wuhan Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Cabio Biotech Wuhan Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Cabio Biotech Wuhan Co Ltd (2013–2024)

Year-by-year earnings quality comparison for Cabio Biotech Wuhan Co Ltd. For live market cap and the full company financial profile, see Cabio Biotech Wuhan Co Ltd (688089) market capitalisation.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2024 1.44x CN¥173.04 Million CN¥120.13 Million ▲ +91.1%
2023 0.75x CN¥68.89 Million CN¥91.37 Million ▼ -73.7%
2022 2.86x CN¥176.40 Million CN¥61.59 Million ▲ +264.1%
2021 0.79x CN¥103.29 Million CN¥131.29 Million ▼ -27.2%
2020 1.08x CN¥145.88 Million CN¥134.94 Million ▼ -1.9%
2019 1.10x CN¥131.95 Million CN¥119.75 Million ▲ +1.5%
2018 1.09x CN¥106.16 Million CN¥97.83 Million ▼ -29.3%
2017 1.53x CN¥100.66 Million CN¥65.59 Million ▲ +13.8%
2016 1.35x CN¥62.53 Million CN¥46.35 Million ▼ -40.9%
2015 2.28x CN¥44.58 Million CN¥19.55 Million ▲ +85.4%
2014 1.23x CN¥46.34 Million CN¥37.66 Million ▲ +45.6%
2013 0.85x CN¥39.48 Million CN¥46.70 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.